3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
20
Neoplasms
9
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Tumors
1
Solid Malignancies
1
Recurrence
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma
1
Advanced Solid Tumors
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
ixabepilone
×
Clear all
NCT00883116
2017-03-09
IXAMPLE2
R-Pharm
Phase 3
Terminated
551 enrolled
13 charts